CRISPR Therapeutics AG (NASDAQ:CRSP) is among the top 10 stocks to buy from Cathie Wood’s stock portfolio. CRISPR made up ...

Crispr Therapeutics AG ( ($CRSP) ) has risen by 9.03%. Read on to learn why. Crispr Therapeutics AG has seen its stock price rise by 9.03% over ...

Despite a challenging CASGEVY launch, high cash burn, and an almost 10% YTD share count growth, CRISPR’s pipeline breadth and ...

Crispr Therapeutics, a leader in CRISPR/Cas9 biotechnology, recently received FDA and EMA approval for Casgevy, the first CRISPR/Cas9-based treatment for TDT and SCD. The partnership with Vertex ...

CRISPR is in the process of a BLA for a potential breakthrough drug. The company isn't profitable and is losing its chief operating officer. CRISPR has more than $1.9 billion in cash. It opened ...

Vertex Pharmaceuticals (NASDAQ: VRTX) has made it to the major leagues in the world of biotech. The company is the leading maker of cystic fibrosis (CF) treatments, with its products generating more ...

CHICAGO, IL—A novel CRISPR/Cas-9-based gene-editing technique seems to safely diminish the production of a protein linked to worsening outcomes in patients with transthyretin (ATTR) amyloidosis ...

DUBLIN--(BUSINESS WIRE)--ERS Genomics Limited (‘ERS’) is pleased to announce ATLATL Innovation Centre (‘ATLATL’) as its non-exclusive agent for licensing ERS’ intellectual property for commercial ...